The U.S. Food and Drug Administration (FDA) granted initial approval to Opdivo (nivolumab) on December 22, 2014. This approval marks the introduction of nivolumab as a new molecular entity, signifying its first entry into the market as a novel therapeutic agent.
Background
Nivolumab, sponsored by Bristol Myers Squibb, received its initial classification as a Type 1 - New Molecular Entity. This designation is given to drugs containing an active moiety that has never before been approved by the FDA. Such a classification indicates that nivolumab represents a novel therapeutic agent, introducing a new chemical structure or biological product into the pharmaceutical landscape of the United States.
What this means
The initial FDA approval of nivolumab as a new molecular entity on December 22, 2014, represents a significant milestone in drug development. As a novel therapeutic agent, its introduction provides a new treatment option for patients. This type of approval indicates that the drug contains an active ingredient not previously marketed in the United States, suggesting a potentially innovative approach to disease management. The approval allows for its commercial availability and clinical use in the United States, making it accessible to healthcare providers and patients who may benefit from this new therapy. Further details regarding its specific approved indication would typically follow such an initial approval.
Source
This information is based on an official document from the U.S. Food and Drug Administration (FDA), specifically a Biologics License Application (BLA) approval record. The approval of Opdivo (nivolumab) was recorded on December 22, 2014, and is accessible via accessdata.fda.gov.